查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951768

異體幹細胞移植市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終使用者、流程、部署類型、設備及階段分類

Allogeneic Stem Cell Transplantation Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Device, Stage
出版日期: | 出版商: Global Insight Services | 英文 301 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

異體幹細胞移植市場預計將從2024年的46億美元成長到2034年的94億美元，複合年成長率約為5.7%。異體幹細胞移植市場涵蓋利用供體幹細胞取代受損骨髓，治療白血病和淋巴瘤等疾病的醫療程序。免疫遺傳學和預處理方案的進步提高了移植成功率，從而推動了市場成長。關鍵趨勢包括個人化醫療方法和臍帶血庫的興起。隨著人們對異體幹細胞移植的認知不斷提高和技術創新，該市場有望實現顯著成長要素，以滿足血液系統疾病領域尚未滿足的醫療需求。

受醫學研究進展和對有效治療方法的需求不斷成長的推動，異體造血幹細胞移植市場預計將迎來顯著成長。骨髓惡性腫瘤是成長最快的細分市場，這主要歸功於其在治療白血病和淋巴瘤等血液癌症方面的重要作用。固態腫瘤緊隨其後，成為第二大細分市場，反映出人們正致力於將異體移植的應用範圍擴展到血液系統疾病以外的領域。在預處理方案方面，清髓性預處理方案因其在提高移植成功率方面的確切療效而佔據主導地位。減低強度預處理方案作為第二大細分市場正在迅速發展，以滿足那些仿單標示外高強度預處理方案的患者的需求。醫院終端用戶憑藉其基礎設施和管理複雜移植手術的專業知識，在市場中佔據主導地位。專科診所因其專注於個人化患者照護和創新治療方法，正逐漸成為極具發展潛力的細分市場。總體而言，該市場的特點是創新、以患者為中心的解決方案和不斷發展的臨床實踐之間動態的相互作用。

市場區隔
類型 造血幹細胞、間質幹細胞、胚胎幹細胞、誘導性多功能幹細胞
產品 幹細胞株、培養基、設備和耗材
服務 冷凍保存、幹細胞庫、細胞增生、細胞分化、諮詢服務
科技 細胞療法、基因編輯、組織工程、生物製程
應用領域 腫瘤科、心血管疾病科、神經系統疾病科、免疫系統疾病科、整形外科
最終用戶 醫院、幹細胞庫、研究機構、生物製藥公司
過程 收集、處理、移植和監測
實施狀態 住院病人、門診病人
裝置 生物反應器、細胞分選裝置
步 臨床前試驗、臨床試驗與商業化

由於競爭激烈的定價策略和創新產品推出，異體幹細胞移植市場的市場佔有率正經歷著動態變化。主要企業正利用先進技術來提高治療效果並擴大市場滲透率。旨在改善患者預後的尖端移植解決方案的策略性引入正在重塑市場格局。醫療基礎設施完善的地區主導地位，而新興市場由於醫療投資的增加正在迅速追趕。競爭基準分析顯示，該市場由少數幾家主要企業主導，它們正透過策略聯盟和併購來爭奪主導地位。監管環境，尤其是在北美和歐洲，對於確保安全性和有效性標準以及塑造市場動態至關重要。該市場的特點是嚴格的合規要求，這既是挑戰也是創新的機會。隨著監管環境的不斷演變，能夠快速適應的企業有望獲得競爭優勢，並為成長和擴張創造有利條件。

主要趨勢和促進因素：

基因編輯技術和免疫療法的進步正在推動異基因幹細胞移植市場的變革性成長。關鍵趨勢包括將CRISPR-Cas9技術應用於改善移植物抗宿主疾病（GVHD）的治療和提高移植效果。個人化醫療的興起正在推動創新，實現量身定做的治療方案，從而提高患者匹配度和移植成功率。血液系統疾病和癌症發生率的不斷上升進一步推動了對異體幹細胞移植的需求。全球人口老化加劇也進一步推動了這項需求。醫療基礎設施的加強和政府政策的支持正在推動先進移植中心的發展，尤其是在新興經濟體。此外，生物技術公司和研究機構之間的合作正在加速臨床試驗和監管核准。細胞庫服務和新型幹細胞來源的開發存在著巨大的發展機會。隨著全球對幹細胞療法的認知和接受度不斷提高，預計該市場將迎來強勁成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 造血幹細胞
    • 間質幹細胞
    • 胚胎幹細胞
    • 誘導性多功能幹細胞
  • 市場規模及預測：依產品分類
    • 幹細胞株
    • 培養基
    • 裝置
    • 消耗品
  • 市場規模及預測：依服務分類
    • 冷凍保存
    • 幹細胞庫
    • 細胞增殖
    • 細胞分化
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 細胞療法
    • 基因編輯
    • 組織工程
    • 生物製程
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經系統疾病
    • 免疫疾病
    • 整形外科應用
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 幹細胞庫
    • 研究所
    • 生物製藥公司
  • 市場規模及預測：依製程分類
    • 收藏
    • 加工
    • 移植
    • 監測
  • 市場規模及預測：依發展狀況
    • 住院病人
    • 門診治療
  • 市場規模及預測：依設備分類
    • 生物反應器
    • 細胞分選裝置
  • 市場規模及預測：依階段分類
    • 臨床前階段
    • 臨床試驗
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Cellectis
  • Gamida Cell
  • Fate Therapeutics
  • Orchard Therapeutics
  • Mesoblast
  • Pluristem Therapeutics
  • Athersys
  • Stempeutics Research
  • Kiadis Pharma
  • Tigenix
  • Cynata Therapeutics
  • Cell Medica
  • Allo Vir
  • Magenta Therapeutics
  • Bellicum Pharmaceuticals
  • Ossium Health
  • Stem Cyte
  • Stem Bio Sys
  • Via Cyte
  • Stemline Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS26595

Allogeneic Stem Cell Transplantation Market is anticipated to expand from $4.6 billion in 2024 to $9.4 billion by 2034, growing at a CAGR of approximately 5.7%. The Allogeneic Stem Cell Transplantation Market encompasses medical procedures using donor stem cells to replace damaged bone marrow, treating conditions like leukemia and lymphoma. This market is driven by advancements in immunogenetics and conditioning regimens, enhancing transplant success rates. Key trends include personalized medicine approaches and increased cord blood banking. As awareness and technological innovations rise, the market is poised for significant growth, addressing unmet needs in hematological disorders.

The Allogeneic Stem Cell Transplantation Market is poised for significant growth, propelled by advancements in medical research and increasing demand for effective treatment options. The hematological malignancies segment is the top-performing sub-segment, driven by its critical role in treating blood cancers, such as leukemia and lymphoma. Solid tumors follow as the second-highest performing sub-segment, reflecting ongoing research efforts to expand allogeneic transplantation applications beyond hematological conditions. Within the conditioning regimen segment, myeloablative conditioning leads, owing to its established efficacy in enhancing engraftment success. Reduced-intensity conditioning is gaining momentum as the second-leading sub-segment, catering to patients who are ineligible for more intensive regimens. The hospital end-user segment dominates due to its infrastructure and expertise in managing complex transplantation procedures. Specialty clinics are emerging as a promising sub-segment, driven by their focus on personalized patient care and innovative treatment approaches. Overall, the market is characterized by a dynamic interplay of innovation, patient-centric solutions, and evolving clinical practices.

Market Segmentation
TypeHematopoietic Stem Cells, Mesenchymal Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells
ProductStem Cell Lines, Culture Media, Instruments, Consumables
ServicesCryopreservation, Stem Cell Banking, Cell Expansion, Cell Differentiation, Consulting Services
TechnologyCell Therapy, Gene Editing, Tissue Engineering, Bioprocessing
ApplicationOncology, Cardiovascular Diseases, Neurological Disorders, Immune Disorders, Orthopedic Applications
End UserHospitals, Stem Cell Banks, Research Institutes, Biopharmaceutical Companies
ProcessHarvesting, Processing, Transplantation, Monitoring
DeploymentInpatient, Outpatient
DeviceBioreactors, Cell Sorters
StagePre-clinical, Clinical Trials, Commercialization

The Allogeneic Stem Cell Transplantation Market is witnessing a dynamic shift in market share, primarily influenced by competitive pricing strategies and innovative product launches. Key players are capitalizing on advanced technologies to enhance treatment efficacy, thereby driving market penetration. The strategic introduction of cutting-edge transplant solutions is reshaping the landscape, with a focus on improving patient outcomes. Regions with robust healthcare infrastructure are leading the way, while emerging markets are rapidly catching up due to increased healthcare investments. Competition benchmarking reveals a landscape dominated by a few key players, each vying for supremacy through strategic alliances and mergers. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics, ensuring safety and efficacy standards. The market is characterized by stringent compliance requirements, which are both a challenge and an opportunity for innovation. As regulatory landscapes evolve, companies that adapt swiftly stand to gain a competitive edge, fostering a fertile ground for growth and expansion.

Geographical Overview:

The allogeneic stem cell transplantation market is witnessing dynamic growth across various regions, each with unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and significant investments in stem cell research. The region's robust regulatory framework and high healthcare expenditure further bolster market growth. Europe follows closely, with strong government support and a growing focus on personalized medicine enhancing its market potential. The Asia Pacific region is rapidly expanding, fueled by increasing healthcare awareness and advancements in medical technologies. Countries like China and India are emerging as key players, supported by large patient populations and favorable government initiatives. In Latin America, Brazil and Mexico are witnessing growth due to rising healthcare investments and improving medical facilities. The Middle East & Africa are also gaining traction, with countries like South Africa recognizing the potential of stem cell therapies in addressing unmet medical needs and driving innovation.

Tariffs and geopolitical tensions are exerting profound effects on the Allogeneic Stem Cell Transplantation Market, particularly in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing domestic biotech capabilities to mitigate tariff-induced cost pressures, while China accelerates its self-sufficiency in stem cell research amid export restrictions. Taiwan, a key player in biomanufacturing, remains vulnerable to geopolitical risks. Globally, the parent market is expanding, driven by rising healthcare demands and technological advancements. By 2035, market evolution will hinge on strategic partnerships and innovation. Middle East conflicts could disrupt global supply chains, indirectly affecting energy prices and production costs, thereby influencing operational strategies in these Asian markets.

Key Trends and Drivers:

The allogeneic stem cell transplantation market is experiencing transformative growth propelled by advancements in gene editing technologies and immunotherapy. Key trends include the integration of CRISPR-Cas9 for enhanced graft-versus-host disease management and improved transplantation outcomes. The rise of personalized medicine is driving innovations, enabling tailored therapeutic approaches that improve patient compatibility and success rates. The demand for allogeneic stem cell transplantation is further fueled by the increasing prevalence of hematological disorders and cancers. This is coupled with a growing geriatric population worldwide. Enhanced healthcare infrastructure and supportive government policies are encouraging the development of advanced transplantation centers, particularly in emerging economies. Additionally, collaborations between biotech firms and research institutions are accelerating clinical trials and regulatory approvals. Opportunities abound in expanding cell banking services and developing novel stem cell sources. The market is poised for robust growth as awareness and acceptance of stem cell therapies continue to rise globally.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Device
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Hematopoietic Stem Cells
    • 4.1.2 Mesenchymal Stem Cells
    • 4.1.3 Embryonic Stem Cells
    • 4.1.4 Induced Pluripotent Stem Cells
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Stem Cell Lines
    • 4.2.2 Culture Media
    • 4.2.3 Instruments
    • 4.2.4 Consumables
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Cryopreservation
    • 4.3.2 Stem Cell Banking
    • 4.3.3 Cell Expansion
    • 4.3.4 Cell Differentiation
    • 4.3.5 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cell Therapy
    • 4.4.2 Gene Editing
    • 4.4.3 Tissue Engineering
    • 4.4.4 Bioprocessing
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurological Disorders
    • 4.5.4 Immune Disorders
    • 4.5.5 Orthopedic Applications
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Stem Cell Banks
    • 4.6.3 Research Institutes
    • 4.6.4 Biopharmaceutical Companies
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Harvesting
    • 4.7.2 Processing
    • 4.7.3 Transplantation
    • 4.7.4 Monitoring
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Inpatient
    • 4.8.2 Outpatient
  • 4.9 Market Size & Forecast by Device (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Cell Sorters
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Pre-clinical
    • 4.10.2 Clinical Trials
    • 4.10.3 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Device
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Device
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Device
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Device
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Device
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Device
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Device
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Device
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Device
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Device
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Device
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Device
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Device
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Device
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Device
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Device
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Device
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Device
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Device
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Device
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Device
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Device
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Device
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Device
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Cellectis
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Gamida Cell
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Fate Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Orchard Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Mesoblast
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Pluristem Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Athersys
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Stempeutics Research
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Kiadis Pharma
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Tigenix
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cynata Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cell Medica
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Allo Vir
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Magenta Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bellicum Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Ossium Health
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Stem Cyte
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Stem Bio Sys
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Via Cyte
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Stemline Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us